New nonsteroidal anti-inflammatory drug in the treatment of different ocular pathology
https://doi.org/10.18008/1816-5095-2016-1-33-37
Abstract
Purpose. Evaluation of efficacy and safety of a new nonsteroidal anti-inflammatory drug (NSAID) Broxinac (bromfenac 0.09 %).
Patients and methods.The study included 79 patients with different mainly inflammatory eye pathology.
All of them have got the instillation of Broxinac 1 per day. The duration of treatment ranged from 1 to 4 weeks.
Results. No corneal complications and allergic reactions during the treatment were observed. Patients did not note any significant discomfort during instillation of Broxinac eye drops. In all cases fast relief of pain was noted. We registered not only quick decrease of exudative reaction in the anterior chamber, but also decrease of inflammation in posterior segment of the eye (fibrinous reaction in vitreous by uveitis).
Conclusion. Broxinac (bromfenac 0.09 %) is new effective and safe ophthalmic NSAID. Broxinac is very convenient eye drops with instillation only once per day. It should be used widely by different inflammation of anterior and posterior segment of the eye and also in the postoperative management.
About the Authors
A. J. Slonimskij
Clinical hospital named after S. P. Botkin, Affiliate № 1 Ophthalmological clinic, Mamonovsky Lane, 7, Moscow, 123001, Russian Federation
Russian Federation
Russian Federation
prof., MD, Clinical hospital named after S. P. Botkin, Affiliate № 1 Ophthalmological clinic, Mamonovsky Lane, 7, Moscow, 123001, Russian Federation
J. B. Slonimskij
Russian Medical Academy of Postgraduate Education, chair of ophthalmology, Barricadnaya street, 2 / 1, Moscow, 125993, Russian Federation
Russian Federation
Russian Federation
prof. MD, Russian Medical Academy of Postgraduate Education, chair of ophthalmology, Barricadnaya street, 2 / 1, Moscow, 125993, Russian Federation
A. S. Obrubov
Clinical hospital named after S. P. Botkin, Affiliate № 1 Ophthalmological clinic, Mamonovsky Lane, 7, Moscow, 123001, Russian Federation
Russian Federation
Russian Federation
doctor, Clinical hospital named after S. P. Botkin, Affiliate № 1 Ophthalmological clinic, Mamonovsky Lane, 7, Moscow, 123001, Russian Federation
References
1. McGhee C., Dean S., Danesh-3, Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25:33‑55.
2. Heier J. S., Topping T. M., Baumann W., Dirks M. S., Chern S. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107 (11):2034‑2038.
3. Wittpenn J. R., Silverstein S., Heier J., Kenyon K. R., Hunkeler J. D., Earl M. Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4 % plus steroid vs steroid alone in low-risk cataract surgery patients. Am. J. Ophthalmol. 2008;146 (4):554‑560.
4. Stewart R. H., Grillone L. R., Shiffman M. L., Donnenfeld E. D., Gow J. A.; Bromfenac Ophthalmic Solution 0.09 % Study Group. The systemic safety of bromfenac ophthalmic solution 0.09 %. J. Ocul. Pharmacol. Ther. 2007;23 (6):601‑612.
5. Radi Z. A., Render J. A. The pathophysiologic role of cyclo-oxygenases in the eye. J. Ocul. Pharmacol. Ther. 2008;24 (2):141‑151.
6. Kim S. J., Flach A. J., Jampol L. M. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv. Ophthalmol. 2010;55 (2):108‑133.
7. Flach A. J. Topical nonsteroidal antiinflammatory drugs in ophthalmology. // Int. Ophthalmol. Clin. 2002;42 (1):1‑11.
8. Baklayan G. A., Patterson H. M., Song C. K., Gow J. A., McNamara T. R. 24‑hour evaluation of the ocular distribution of (14) C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J. Ocul. Pharmacol. Ther. 2008;24 (4):392‑398.
9. Cho H., Wolf K. J., Wolf E. J. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin. Ophthalmol. 2009;3:199‑210.
10. Ray S., D’Amico D. J. Pseudophakic cystoid macular edema. Semin. Ophthalmol. 2002;17:167‑180.
11. Mentes J., Erakgun T., Afrashi F., Kerci G., Incidence of cystoid macular edema after uncomplicated phacoemulsification. Ophthalmologica. 2003;217:408‑412.
12. Ursell P. G., Spalton D. J., Whitcup S. M., Nussenblatt R. B., Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J. Cataract Refract. Surg. 1999;25:1492‑1497.
13. Kessel L., Tendal В., Jorgensen K. J. et al. Post- cataract prevention of inflamation and macular edema by steroid and NSAID: a systematic review. Ophthalmology, 2014, Oct; 121 (10):1915‑1924.
14. Kim S. J., Bressler N. M. Optical coherence tomography and cataract surgery. // Curr. Opin. Ophthalmol. 2009;20:46‑51.
15. Lobo C. L., Faria P. M., Soares M. A., Bernardes R. C., Cunha-Vaz J. G. Macular alterations after small-incision cataract surgery. J. Cataract Refract Surg. 2004;30 (4):752‑760.
16. Perente I., Utine C. A., Ozturker C., Cakir M., Kaya V., Eren H., Kapran Z., Yilmaz O. F. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr. Eye Res. 2007;32 (3):241‑247.
17. Walter K. Five surgeons, 5 year retrospective analysis of post-op CME rates using various topical regiments. // XXXI Congress of the ESCRS — Amsterdam, 2013. — Session Title: Cystoid Macular Oedema and Infection. 06 / 10 / 2013. Free Paper Presentation.
18. Mian S. I., Gupta A., Pineda R. Corneal ulceration and perforation with ketorolac tromethamine (Acular) use after PRK. Cornea. 2006;25 (2):232‑234.
19. Lee W. B., Himmel K. Corneal ulceration and perforation with ketorolac tromethamine. Cornea. 2006;25 (10):1268.
20. Asai T., Nakagami T., Mochizuki M., Hata N., Tsuchiya T., Hotta Y. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea. 2006;25 (2):224‑227.
21. Di Pascuale M. A., Whitson J. T., Mootha V. V. Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. Eye Contact Lens. 2008;34 (2):129‑130.
22. Schechter B. A., Trattler W. Efficacy and safety of bromfenac for the treatment of corneal ulcer pain. Adv. Ther. 2010;27 (10):756‑761.
Review
For citations:
Slonimskij A.J., Slonimskij J.B., Obrubov A.S. New nonsteroidal anti-inflammatory drug in the treatment of different ocular pathology. Ophthalmology in Russia. 2016;13(1):33-37. (In Russ.) https://doi.org/10.18008/1816-5095-2016-1-33-37
Views:
1357
Email this article 